Purpose To research the 2-12 months outcomes of three monthly intravitreal ranibizumab injections followed by as-needed reinjections to treat polypoidal choroidal vasculopathy (PCV). PCV. During 12 months 2, the magnitude of the improvement was lower compared with 12 months 1. An as-needed reinjection schedule might not prevent polypoidal lesions or BVNs from regrowing. Further investigations… Continue reading Purpose To research the 2-12 months outcomes of three monthly intravitreal